Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation

NCT ID: NCT02802176

Last Updated: 2023-07-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2022-08-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate implantation rate with intra-vaginal culture (IVC) with the INVOcell device versus traditional In-Vitro Fertilization (IVF) while using minimal stimulation protocols

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase IV, single center randomized controlled trial evaluating intra-vaginal culture (IVC) using INVOcell versus traditional In-Vitro Fertilization (IVF) using oral stimulation or minimal gonadotropin stimulation protocols. The pilot aims to includes 40 women who will be randomized to either the intra-vaginal culture group (N=20) using INVOcell or to the traditional IVF group (N=20).

Primary aim is implantation rate, which is defined by number gestational sacs seen on early pregnancy ultrasound divided by number of embryos transferred.

Secondary aims are:

* Embryo quality, which is measured by system similar to the Gardner grading system at cleavage stage. Reported quality will be converted to the simplified SART embryo scoring system which provides an overall categorical embryo grade of "Good", "Fair" or "Poor".
* Fertilization rate, which is defined by the total number of fertilized oocytes divided by total number of mature oocytes retrieved. This comparison will take place on day-3, as that is when the IVC embryos will be assessed.
* Clinical pregnancy rate, which is defined by the number of fetal poles with heartbeat seen on ultrasound divided by the number of embryos transferred.
* Live birth rate, which is defined by the number of living babies delivered divided by the number of transfers

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Arm 1: intra-vaginal culture using INVOcell device. Arm 2: Traditional In-Vitro Fertilization (IVF) culture in an embryology laboratory
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intra-vaginal culture - INVOcell device

3 day intra-vaginal incubation using the INVOcell device

Group Type EXPERIMENTAL

INVOcell device

Intervention Type DEVICE

intra-vaginal culture of embryos using INVOcell device

Traditional IVF culture

3 day traditional IVF incubation

Group Type ACTIVE_COMPARATOR

Traditional IVF

Intervention Type OTHER

traditional culture of embryos in-vitro

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INVOcell device

intra-vaginal culture of embryos using INVOcell device

Intervention Type DEVICE

Traditional IVF

traditional culture of embryos in-vitro

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal uterine cavity
* One or more years of infertility
* Normal male partner semen analysis

Exclusion Criteria

* Age \<18 years old or \>37 years old
* Antral Follicle Count (AFC) \<8
* Abnormal male partner semen analysis or use of donor sperm
* Vaginal inflammation or genital (vaginal, uterine, tubal) infection
* Uncontrolled chronic disease (such as uncontrolled diabetes or hypertension)
* Uterine anatomic abnormalities
* Allergy to plastics or inability to use diaphragm retention device
* Untreated hydrosalpinx
* Current alcohol abuse (defined by \>14 drinks/week)
* Prior history of IVF cycle where fertilization did not occur
* History of recurrent pregnancy loss
Minimum Eligible Age

18 Years

Maximum Eligible Age

37 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marcelle Cedars, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Francisco - Center for Reproductive Health

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://crh.ucsf.edu/

University of California San Francisco Center for Reproductive Health

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB 166094

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immune Modulators and IVF
NCT02626702 TERMINATED